Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: GlobeNewswire
Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026Praxis to present 3 oral presentations and 12 posters at AAN 2026Visit Praxis at Booth #2324 for an in-booth speaker showcase featuring Phase 3 Essential3 results for ulixacaltamide, plus scientific exchange on essential tremor. BOSTON, April 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will present expanded analyses from the Phase 3 Essential3 program of ulixacaltamide in essential tremor, alongside new data from its advancing CNS pipeline, at the 2026 AAN Annual Meeting, taking place April 18–22, 2026, in Chicago, Illinois. Essential tremor affects approximately 7 million people in the United States and is one of the most common moveme
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by Deutsche Bank Aktiengesellschaft.MarketBeat
- Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $510.00 price target on the stock.MarketBeat
- Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential TremorGlobeNewswire
- Praxis Precision Medicines (PRAX) was upgraded by Raymond James Financial, Inc. to "strong-buy".MarketBeat
- Praxis Precision Medicines (PRAX) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating and a $815.00 price target on the stock.MarketBeat
PRAX
Earnings
- 2/19/26 - Miss
PRAX
Sec Filings
- 4/14/26 - Form 8-K
- 4/6/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- PRAX's page on the SEC website